The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

Here is what can happen to the body once you finish a course of Ozempic as a simulation reveals what the diabetes drug does ...

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.

Ozempic, a diabetes drug, shows promise for liver disease. Research indicates it can reverse non-alcoholic steatohepatitis. A ...

Medically reviewed by Femi Aremu, PharmD Ozempic and Wegovy are both glucagon-like peptide-1 (GLP-1) receptor agonists and ...

Shares in Novo Nordisk were still up after Q1 2025 witnessed a total revenue jump by 18%, compared to Q1 2024.

The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...

With more and more people signing up for weight loss drugs, the potential side effects are starting to attract attention.

As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...

Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...

Novo Nordisk's (NVO) investors are worried its competition with Eli Lilly (LLY) is heating up and that the first-to-market ...

Novo Nordisk cut 2025 sales forecast citing competition from compounded versions of its Wegovy weight-loss drug. Invezz takes ...